Glaukos price target raised to $85 from $80 at Mizuho

Mizuho analyst Anthony Petrone raised the firm’s price target on Glaukos to $85 from $80 and keeps a Neutral rating on the shares. The company reported a “clean beat and raise” quarter and proposed reimbursement changes could further benefit Glaukos ahead of the potential iDose launch in early 2024, the analyst tells investors in a research note.